-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Ebola -X- _ O
virus -X- _ O
causes -X- _ O
a -X- _ O
hemorrhagic -X- _ O
fever -X- _ O
syndrome -X- _ O
that -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
high -X- _ O
mortality -X- _ O
in -X- _ O
humans. -X- _ O
In -X- _ O
the -X- _ O
absence -X- _ O
of -X- _ O
effective -X- _ O
therapies -X- _ O
for -X- _ O
Ebola -X- _ O
virus -X- _ O
infection -X- _ O
, -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
a -X- _ O
vaccine -X- _ O
becomes -X- _ O
an -X- _ O
important -X- _ O
strategy -X- _ O
to -X- _ O
contain -X- _ O
outbreaks. -X- _ O
Immunization -X- _ O
with -X- _ O
DNA -X- _ B-Intervention
and -X- _ I-Intervention
/ -X- _ I-Intervention
or -X- _ I-Intervention
replication-defective -X- _ I-Intervention
adenoviral -X- _ I-Intervention
vectors -X- _ I-Intervention
( -X- _ I-Intervention
rAd -X- _ I-Intervention
) -X- _ I-Intervention
encoding -X- _ I-Intervention
the -X- _ I-Intervention
Ebola -X- _ I-Intervention
glycoprotein -X- _ I-Intervention
( -X- _ I-Intervention
GP -X- _ I-Intervention
) -X- _ I-Intervention
and -X- _ I-Intervention
nucleoprotein -X- _ I-Intervention
( -X- _ I-Intervention
NP -X- _ I-Intervention
) -X- _ I-Intervention
has -X- _ O
been -X- _ O
previously -X- _ O
shown -X- _ O
to -X- _ O
confer -X- _ O
specific -X- _ O
protective -X- _ O
immunity -X- _ O
in -X- _ O
nonhuman -X- _ B-Patient
primates. -X- _ I-Patient
GP -X- _ B-Intervention
can -X- _ O
exert -X- _ O
cytopathic -X- _ O
effects -X- _ O
on -X- _ O
transfected -X- _ O
cells -X- _ O
in -X- _ O
vitro -X- _ O
, -X- _ O
and -X- _ O
multiple -X- _ O
GP -X- _ B-Intervention
forms -X- _ O
have -X- _ O
been -X- _ O
identified -X- _ O
in -X- _ O
nature -X- _ O
, -X- _ O
raising -X- _ O
the -X- _ O
question -X- _ O
of -X- _ O
which -X- _ O
would -X- _ O
be -X- _ O
optimal -X- _ O
for -X- _ O
a -X- _ O
human -X- _ O
vaccine. -X- _ O
METHODS -X- _ O
AND -X- _ O
FINDINGS -X- _ O
: -X- _ O
To -X- _ O
address -X- _ O
this -X- _ O
question -X- _ O
, -X- _ O
we -X- _ O
have -X- _ O
explored -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
mutant -X- _ O
GPs -X- _ O
from -X- _ O
multiple -X- _ O
Ebola -X- _ O
virus -X- _ O
strains -X- _ O
with -X- _ O
reduced -X- _ O
in -X- _ O
vitro -X- _ O
cytopathicity -X- _ O
and -X- _ O
analyzed -X- _ O
their -X- _ O
protective -X- _ O
effects -X- _ O
in -X- _ O
the -X- _ O
primate -X- _ B-Patient
challenge -X- _ O
model -X- _ O
, -X- _ O
with -X- _ O
or -X- _ O
without -X- _ O
NP. -X- _ O
Deletion -X- _ O
of -X- _ O
the -X- _ O
GP -X- _ O
transmembrane -X- _ O
domain -X- _ O
eliminated -X- _ O
in -X- _ O
vitro -X- _ O
cytopathicity -X- _ O
but -X- _ O
reduced -X- _ O
its -X- _ O
protective -X- _ O
efficacy -X- _ O
by -X- _ O
at -X- _ O
least -X- _ O
one -X- _ O
order -X- _ O
of -X- _ O
magnitude. -X- _ O
In -X- _ O
contrast -X- _ O
, -X- _ O
a -X- _ O
point -X- _ O
mutation -X- _ O
was -X- _ O
identified -X- _ O
that -X- _ O
abolished -X- _ O
this -X- _ O
cytopathicity -X- _ O
but -X- _ O
retained -X- _ O
immunogenicity -X- _ O
and -X- _ O
conferred -X- _ O
immune -X- _ O
protection -X- _ O
in -X- _ O
the -X- _ O
absence -X- _ O
of -X- _ O
NP. -X- _ O
The -X- _ O
minimal -X- _ O
effective -X- _ O
rAd -X- _ O
dose -X- _ O
was -X- _ O
established -X- _ O
at -X- _ O
10 -X- _ O
( -X- _ O
10 -X- _ O
) -X- _ O
particles -X- _ O
, -X- _ O
two -X- _ O
logs -X- _ O
lower -X- _ O
than -X- _ O
that -X- _ O
used -X- _ O
previously. -X- _ O
CONCLUSIONS -X- _ O
: -X- _ O
Expression -X- _ B-Outcome
of -X- _ I-Outcome
specific -X- _ I-Outcome
GPs -X- _ I-Outcome
alone -X- _ I-Outcome
vectored -X- _ I-Outcome
by -X- _ I-Outcome
rAd -X- _ I-Outcome
are -X- _ I-Outcome
sufficient -X- _ I-Outcome
to -X- _ I-Outcome
confer -X- _ I-Outcome
protection -X- _ I-Outcome
against -X- _ I-Outcome
lethal -X- _ I-Outcome
challenge -X- _ I-Outcome
in -X- _ O
a -X- _ O
relevant -X- _ O
nonhuman -X- _ O
primate -X- _ O
model. -X- _ O
Elimination -X- _ B-Outcome
of -X- _ I-Outcome
NP -X- _ I-Outcome
from -X- _ I-Outcome
the -X- _ I-Outcome
vaccine -X- _ I-Outcome
and -X- _ I-Outcome
dose -X- _ I-Outcome
reductions -X- _ I-Outcome
to -X- _ I-Outcome
10 -X- _ I-Outcome
( -X- _ I-Outcome
10 -X- _ I-Outcome
) -X- _ I-Outcome
rAd -X- _ I-Outcome
particles -X- _ I-Outcome
do -X- _ I-Outcome
not -X- _ I-Outcome
diminish -X- _ I-Outcome
protection -X- _ I-Outcome
and -X- _ I-Outcome
simplify -X- _ I-Outcome
the -X- _ I-Outcome
vaccine -X- _ I-Outcome
, -X- _ O
providing -X- _ O
the -X- _ O
basis -X- _ O
for -X- _ O
selection -X- _ O
of -X- _ O
a -X- _ O
human -X- _ O
vaccine -X- _ O
candidate -X- _ O
. -X- _ O

